PCSK9 and Cognitive impairment: In this study, we quantitatively evaluated the safety profile of PCSK9 inhibitors in real-world settings from an age- and gender-oriented perspective using data from the FAERS database, and compared their risks of cognitive impairment, musculoskeletal disorders and diabetes with various statins and ezetimibe, where PCSK9 inhibitors performed satisfactorily overall.